Zelluna ASA (FRA:7UM0) Other Financing: €4.75 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7UM0 Zelluna ASA FRA:7UM0
30 GF Score
Price €1.91
! 2 Warning Signs
View Full Analysis

What is Zelluna ASA Other Financing?

Zelluna ASA FRA:7UM0 -2.55% 30 Other Financing is €4.75 Mil as of Mar. 2026. GuruFocus rates FRA:7UM0 with a GF Score™ of 30/100. The stock has 2 warning signs investors should review.

Zelluna ASA's Other Financing for the three months ended in Mar. 2026 was €-0.00 Mil.

Zelluna ASA's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was €4.75 Mil.

Zelluna ASA Other Financing Historical Data

* Premium members only.

The historical data trend for Zelluna ASA's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelluna ASA Other Financing Chart

Zelluna ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.10 -0.01 -0.03 -0.00 -0.22

Zelluna ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 0.00 -0.00 4.75 -0.00
FRA:7UM0
30GF Score
Zelluna ASA FRA:7UM0
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelluna ASA Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.75 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €4.75 Mil mean?
Zelluna ASA (FRA:7UM0) has a Other Financing of €4.75 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Zelluna ASA and its competitors.
Is Zelluna ASA's Other Financing too high?
Zelluna ASA's current Other Financing is €4.75 Mil. Overall, Zelluna ASA has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Zelluna ASA's Other Financing compare to VRTX and REGN?
Zelluna ASA's Other Financing of €4.75 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Zelluna ASA and its competitors. Zelluna ASA's current Other Financing is €4.75 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelluna ASA stock overvalued right now?
Zelluna ASA (FRA:7UM0) has a current Other Financing of €4.75 Mil. The current Other Financing is €4.75 Mil. Zelluna ASA's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Zelluna ASA (FRA:7UM0), the current Other Financing is €4.75 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelluna ASA Business Description

Other Exchanges ZLNA:Norway
Address Ullernchausseen 64, Oslo Cancer Cluster Innovation Park, Oslo, NOR, 0379
Zelluna ASA is a biotechnology company established to eliminate solid cancers by unleashing the powerful elements of the immune system through pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell therapies (TCR-NK). Its TCR-NK products are composed of healthy donor-derived NK cells that are genetically engineered to express a tumour-specific TCR that enable the TCR-NK cells to identify and eliminate cancer cells in the body of the patient. Its programme ZI-MA4-1, the first MAGE-A4-targeting TCR-NK therapy for solid tumours with high unmet medical need. Its other programmes include ZI-KL1-1, and ZI-PR-1.
30GF Score

Get the complete analysis for FRA:7UM0

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.91
Price